Latest Distribution Agreements News

FBR has cut its annual loss dramatically and moved its first Mantis welding robot into commissioning, but year-end cash of just A$27,814 leaves the company dependent on fundraising, tax funding and successful delivery. Its audited accounts flag a material uncertainty over whether the robotics developer can continue as a going concern.

Thrive Tribe Technologies has repositioned WooBoard and REFFIND towards defence and workforce software, but its FY26 annual report flags a material uncertainty over the company’s ability to continue as a going concern. The pivot follows a $3.66 million loss, $2.57 million operating cash outflow and another $1 million placement after year-end.

Merino & Co cut its FY2026 loss by 20% as China revenue more than doubled, but group revenue declined and cash reserves fell sharply. The auditor highlighted a material uncertainty over the company’s ability to continue as a going concern.

Novatti has reported a statutory profit and positive EBITDA for FY26 after cutting low-margin revenue and concentrating on Payments AU/NZ. The turnaround is substantial, but an auditor-flagged going-concern uncertainty, upcoming debt maturities and negative operating cash flow leave the recovery unfinished.

Firebrick Pharma has approved a phased push into US retail pharmacies after Nasodine online sales grew by more than 200% in FY26. Up to six regional pharmacy groups representing about 700 stores have expressed strong interest in early orders, although no binding orders have been disclosed.

Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Zimi has secured an exclusive three-year distribution agreement with Directed for retail, direct-to-consumer and direct-to-business sales across Australia and New Zealand. The deal gives its next-generation Matter devices access to more than 10,000 retail outlets, although commercial terms and guaranteed sales volumes remain undisclosed.

Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.

Memphasys has signed a three-year exclusive distribution agreement covering the Czech Republic, Slovakia and Kazakhstan, with minimum purchases worth approximately A$674,000. The deal expands Felix’s European footprint while adding dedicated commercial leadership in the region.

Thrive Tribe Technologies (ASX:1TT) has landed a three-year exclusive distribution agreement with Canadian NATO-registered defence contractor Effective Acceleration Ventures (EAV) to roll out its WooBoard and REFFIND platforms across NATO military forces.

Immuron Limited has inked an exclusive US distribution deal for PROIBS®, a European-certified medical device targeting abdominal discomfort, marking a key step in its digestive health portfolio growth.